Clean Yield Group Buys 12,643 Shares of Hologic, Inc. (NASDAQ:HOLX)

Clean Yield Group increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 49.1% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 38,380 shares of the medical equipment provider’s stock after purchasing an additional 12,643 shares during the period. Clean Yield Group’s holdings in Hologic were worth $3,126,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in shares of Hologic in the second quarter worth $25,000. iA Global Asset Management Inc. purchased a new stake in shares of Hologic during the first quarter worth about $37,000. Sunbelt Securities Inc. purchased a new position in shares of Hologic in the second quarter worth $37,000. Cranbrook Wealth Management LLC purchased a new stake in shares of Hologic during the 2nd quarter valued at about $47,000. Finally, Mather Group LLC. purchased a new stake in Hologic during the first quarter valued at approximately $48,000. Institutional investors own 94.73% of the company’s stock.

Insider Activity

In other news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,280 shares of company stock worth $1,469,973 over the last ninety days. Corporate insiders own 1.75% of the company’s stock.

Hologic Stock Down 0.4 %

Shares of HOLX opened at $79.88 on Tuesday. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock’s 50-day moving average price is $81.28 and its 200-day moving average price is $77.48. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67. The company has a market capitalization of $18.64 billion, a price-to-earnings ratio of 40.76, a PEG ratio of 2.58 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.93 EPS. On average, sell-side analysts predict that Hologic, Inc. will post 4.09 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on HOLX. Royal Bank of Canada reiterated a “sector perform” rating and set a $82.00 price target on shares of Hologic in a report on Friday, August 16th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, September 17th. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Finally, Evercore ISI lifted their price target on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $87.50.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.